Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Prescient Therapeutics (ASX:PTX) has reported a 32.3% reduction in net loss for the half-year ended 31 December 2024, with ...

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

Q4 2024 Management View CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical advancements in its obesity pipeline, particularly with ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 EPIC (EPIlepsy Cell therapy) trial as the primary basis for ...

Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...